OKYO Pharma Ltd Logo

OKYO Pharma Ltd

Clinical-stage biopharma developing drugs for eye diseases and chronic pain.

OKYO | US

Overview

Corporate Details

ISIN(s):
US6793451088
LEI:
Country:
United States of America
Address:
55 PARK LANE, LONDON

Description

OKYO Pharma Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for inflammatory eye diseases and chronic pain. The company's primary focus is on addressing significant unmet medical needs in neuropathic corneal pain (NCP) and dry eye disease (DED). Its lead product candidate, Urcosimod (OK-101), is a novel G protein-coupled receptor (GPCR) agonist that targets the chemerin receptor to produce anti-inflammatory and pain-reducing effects. OKYO is the first company to receive Investigational New Drug (IND) clearance from the FDA to clinically evaluate a drug specifically for NCP, a condition with no approved treatments. Urcosimod has also been granted Fast Track Designation by the FDA for the treatment of NCP.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2018-08-20 02:00
OKYO - AGM Notice 2018
English 256.3 KB
2018-07-31 20:05
Final Results
English 302.1 KB
2018-07-13 02:00
Issuer Document
English 1.7 MB
2018-03-09 12:01
Result of General Meeting and Corporate Update
English 22.8 KB
2018-03-02 13:47
Change of Broker
English 15.0 KB
2018-02-21 18:00
Proposed cancellation, suspension, notice of GM
English 79.1 KB
2018-02-21 18:00
Suspension - Okyo Pharma Corporation
English 8.6 KB

Automate Your Workflow. Get a real-time feed of all OKYO Pharma Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for OKYO Pharma Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for OKYO Pharma Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.